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Abstract
Objective—Recent outbreaks of Clostridium difficile infection (CDI) have been difficult to
control, and data indicate the importance of different sources of transmission may have changed.
Our objectives were to evaluate the contributions of asymptomatic and symptomatic C. difficile
carriers to new colonizations and to determine the most important epidemiological factors
influencing C. difficile transmission.
Design—Retrospective cohort
Setting and Patients—All patients admitted to medical wards at a large tertiary care hospital in
the US from Jan 1 to Dec 31, 2008.
Methods—Data from six medical wards and published literature were used to develop a
compartmental model of C. difficile transmission. Patients could be in one of five transition states
in the model: resistant to colonization (R), susceptible to colonization (S), asymptomatically
colonized without protection against CDI (C−), asymptomatically colonized with protection
against CDI (C+), and patients with CDI (D).
Results—The contributions of C−, C+ and D patients to new colonizations were similar. The
simulated basic reproduction number ranged from .55 to 1.99, with median 1.04. These values
suggest that transmission within the ward alone from patients with CDI cannot sustain new C.
difficile colonizations, and therefore, the admission of colonized patients plays an important role
in sustaining transmission in the ward. The epidemiological parameters that ranked as the most
influential were the proportion of admitted C− and the transmission coefficient for asymptomatic
carriers.
Conclusion—Our study underscores the need to further evaluate the role of asymptomatically
colonized patients in C. difficile transmission in the healthcare setting.
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INTRODUCTION
Clostridium difficile is the leading cause of infectious diarrhea in hospitals, and has become,
along with methicillin-resistant Staphylococcus aureus, one of the most common causes of
health-care associated infections.1,2 The incidence and severity of Clostridium difficile
infection (CDI) has increased dramatically since 2000, and CDI is estimated to cause as
many as 20,000 deaths and cost as much as $3.2 billion per year in US acute care facilities
alone.3–5 CDI outbreaks have become more common, and infection control-based CDI
prevention efforts appear to be less effective than in the past.2,6
Studies on C. difficile nosocomial transmission were undertaken in the late eighties.7–9
Clabots et al provided evidence that asymptomatically colonized new admissions to a ward
were an important source of transmission.9 Patients with symptomatic CDI, compared to
asymptomatic C. difficile carriers, were more likely to contaminate their surroundings and
hands of healthcare workers with C. difficile.7,8 Therefore it was concluded that
symptomatic CDI patients were the main source of C. difficile transmission. As a result,
current CDI prevention efforts, such as isolation and contact precautions, target only
symptomatic CDI patients10. Changes in the epidemiology of C. difficile and health care
delivery since the original transmission studies were conducted may have shifted the relative
contribution of symptomatic CDI patients and asymptomatic carriers.11 For example, since
2002 alcohol-based hand hygiene products have been recommended as the primary form of
hand hygiene in healthcare settings.12Clostridium difficile spores are resistant to the
bactericidal effects of alcohol.13 Use of alcohol-based hand hygiene products after caring for
asymptomatic C. difficile carriers may increase their contribution to C. difficile
transmission.13 Conversely, rapid identification of patients with CDI and placing these
patients in contact precautions may have reduced the contribution of C. difficile
transmission from patients with CDI.10,14
Mathematical models of disease transmission provide a conceptual framework to understand
and quantify transmission and intervention strategies. Mathematical models have helped to
understand the epidemiology of other nosocomial pathogens such as vancomycin-resistant
enterococcus15,16 and methicillin-resistant Staphylococcus aureus.17 To date, efforts to
model C. difficile transmission have been limited; Starr et al modeled the C. difficile
transmission in a geriatric ward.18 They quantified C. difficile transmission within and
between rooms, but the relative contribution of asymptomatic and clinical patients as
sources of new infections was not addressed.18 In addition, the data were collected prior to
the changes in CDI epidemiology.19
Our objectives were to provide a framework to evaluate the relative contributions of
asymptomatically and symptomatically colonized patients to new colonizations and to
determine the most important epidemiological factors influencing C. difficile transmission at
the ward level. For that purpose, we developed an epidemiological model of C. difficile and
evaluated the impact of different epidemiological parameters on C. difficile transmission.
We used recent data from a large tertiary care hospital and published literature to estimate
model parameters.
METHODS
Data
Data were collected retrospectively from six medicine wards at Barnes-Jewish Hospital in
St. Louis, Missouri from January 1 through December 31, 2008. The data were collected
electronically from the hospital's medical informatics databases, and included patient
demographics, dates of hospital and ward admission, discharge, and transfers, laboratory
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tests, and medication exposures. Two wards had 26 beds, one ward had 29 beds, and three
wards had 30 beds. On average there were 153 admissions per ward per month, including,
109 per month whose length of stay was greater than 48 hours. The microbiology laboratory
at Barnes Jewish Hospital only tests diarrheal stool for the presence of C. difficile toxin
(Remel ProSpecT Clostridium difficile Toxin A/B). Testing stool for the presence of C.
difficile toxin requires a physician order. During the study period patients diagnosed with
CDI were placed into isolation and contact precautions were initiated. Isolation and
precautions were typically initiated only after the patient was diagnosed with CDI. The
dataset included 11046 admissions. The mean age of patients was 57 years old. They have a
mean Charlson Comorbidity Score of 1.8 and 54 % were female. On average there were 2.2
incident cases of clinical CDI per month on each ward (157 cases total for all six wards) and
2.2 prevalent cases (present on admission) of clinical CDI per month on each ward.
Epidemiological Model
We developed an epidemiological model for the C. difficile transmission in the ward (Figure
1). In an epidemiological model, the patient population is divided in different transition
states according their infection status. The C. difficile epidemiological model included the
following transition states: resistant to colonization (R), susceptible to colonization (S),
asymptomatically colonized without protection against CDI (C−), asymptomatically
colonized with protection against CDI (C+) and diseased (D, i.e. CDI) (Table 1). Resistant
individuals were defined as patients who had not received antimicrobial treatment and had a
normal intestinal microbiota that provides “colonization resistance” against C. difficile.20
Although patients with normal flora can be colonized with C. difficile, this appears to be
transient and associated with a much lower risk of development of CDI compared to patients
with altered flora.8,9,21 Hence, we assumed that individuals with a normal intestinal
microbiota were resistant to C. difficile colonization. Susceptible patients received
antimicrobial treatment and could be colonized by C. difficile. Antibiotic treatment disrupts
the normal microbiota making patients significantly more susceptible to C. difficile
colonization and development of CDI after colonization.22 Three types of colonized patients
were included in the model: C−, C+, and D. We considered two types of asymptomatically
colonized patients based on the risk of developing CDI. Colonized patients could or could
not mount a protective response. Asymptomatically colonized patients who did not mount an
immune response could develop disease. Diseased patients were treated with antibiotics.
Depending on treatment success, diseased patients could continue to be diseased or become
susceptible again at the end of therapy. Patients could be admitted and discharged in any of
the five states, and C+ were assumed to be colonized during all the duration of the
hospitalization.7–9 The mathematical model is presented in the Appendix.
Parameterization
Model parameters are described in Table 2. The proportions of admitted patients defined as
resistant and diseased were obtained from the hospital data. Patients who did not receive
antibiotics during their admission were considered resistant patients. Patients with a positive
stool sample within 48 hours after admissions were considered to be admitted diseased.23
The antibiotic prescription rate was obtained from the hospital dataset based on the
admission rate and the percentage of individuals that received antibiotic during their stay.
Patients were considered susceptible after being exposed to antibiotics. Microflora returns to
normal within 1 to 49 days after the end of the treatment depending on the antimicrobial
group.22 We set the restoration rate to 0.033 day−1, which means that the microflora of each
patient recovers 3.3 % each day and therefore it returns to normal after 30 days in average.
Vancomycin and metronidazole are considered the “standard” treatments for CDI cases. For
80% of patients with CDI, diarrhea symptoms resolve within a typical 10-day treatment,
regardless of antibiotic type.24 Therefore the treatment rate was set to 0.10 day−1, the
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inverse of the treatment duration, and the probability of successful treatment to 0.80. The
clinical disease rate is the inverse of the incubation period.9,25 The mean fraction of
colonized patients that mounted an immune response was set at 0.60; 60 % of the patients
that became colonized had detectable antibody responses.26 Discharge rates were obtained
from the hospital dataset. Discharge rates are the inverse of the length of stay. Patients
without antimicrobial treatment (R) during the hospitalization had the shortest length of stay
(3 days). Susceptible and colonized patients had an average length of stay of 6.7 days. For
clinical CDI, the length of stay was 14.7 days (Table 2). Default values for transmission
coefficients and the proportion of admitted patients as S, C−, and C+ were set to match
observed attack rates.
Simulations
The model predicted the following outcomes: the basic reproduction number (R0), the
average number of secondary cases of colonization generated by each type of admitted
colonized patients (C−, C+, D), and the number of CDI cases per 1000 admissions. The basic
reproduction number is the average number of secondary cases of colonization generated by
one primary case of C. difficile colonization in a C. difficile-free ward. It conveys
information regarding the transmissibility of the pathogen in a specific setting. The higher
the R0, the greater the pathogen transmissibility is. To quantify R0 and the contribution of
the three types of admitted colonized patients to new colonizations, we constructed the so-
called next generation matrix for the model.27 The next generation matrix allows us to
express both outcomes as a function of the epidemiological model parameters.27 Then, we
performed a sensitivity analysis to assess which epidemiological parameters were the most
influential. The method used in the sensitivity analysis was the Sobol's sensitivity indices.28
Sobol's indices are an ANOVA-like decomposition and partition the variability of the model
output (i.e, expected secondary colonizations and R0) in main effects of the parameters and
total effects (including interactions between parameters). In addition, model simulations of
the stochastic model (see appendix A.2 for details) were performed to evaluate the effect of
varying the proportion of admitted colonized and diseased patients and other parameters on
the number of CDI cases per 1000 admissions.
RESULTS
Model simulations are presented in Figures 2, 3, 4, and 5
The R0 ranged from 0.55 to 1.99 (Figure 2). For almost 50 % of the simulations, R0 was less
than one. One is a threshold value because if R0 is greater than one, on average one case
leads to more than one secondary case, and therefore, the number of cases will grow in the
population. The variation in R0 was explained the most by the variation in transmission
parameters (βc and βd) and duration of the stay of the colonized patients (k and kd) (Figure
2). Specifically, the two most influential parameters were the transmission coefficient for
asymptomatic patients (βc) and the discharge rate for susceptible and colonized patients (k).
The proportion of the R0 variation that was not explained directly by the parameters was a
very small percentage (1 %) and was due to interactions among parameters (Figure 2).
Figure 3 displays the average number of new colonizations that each type of colonized
patient can produce once admitted in a C. difficile free ward. These values may not be
attainable because the wards are not completely occupied by susceptible individuals and
have a continuous inflow of new admissions and outflow of discharges. Nevertheless, they
provide a way to rank the contribution of different types of admitted colonized individuals to
new colonizations. The three types of colonized patients contributed similarly to new
colonizations, each resulting in an average of 0.40 new C− colonizations and 0.60 new C+
colonizations (Figure 3). Admitted C− patients contribute to new cases as C− and D (if they
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move into the D state). The parameters that explain most of the variation in the contribution
of the three types of colonized patients were the fraction of newly colonized patients that
mount an immune response (f), the transmission coefficient for diseased patients (βd), the
transmission coefficient for asymptomatic carriers (βc), and the discharge rate of colonized
and susceptible patients (k).
Figures 4 and 5 display the results of the stochastic simulations. The proportion of patients
admitted as C− was the epidemiological parameter with the strongest influence on the
number of new CDI cases (per 1000 admissions). For the scenario with the baseline
parameters, the median for the number of CDI cases was 17.85 per 1000 admissions (Figure
4). Increasing the proportion of admitted C− by 0.01 increases the median attack rate to
27.54 new cases per 1000 admissions. Changing the admission for C+ and D had similar
effects, but their influence on the number of CDI cases was lower than C− (Figure 4).
Among all the other parameter evaluated, transmission coefficients, clinical disease rate and
the fraction of newly colonized patients that mount an immune response were the most
influential (Figure 5).
DISCUSSION
We present a mathematical model of the transmission of C. difficile in health-care settings.
We considered three types of colonization during hospitalization (Table 1). We omitted
other states and transitions that may be relevant at the community level. Proposed models
for community-associated C. difficile included states such as clinically resolved colonized
(successfully treated CDI but patient remains colonized) and transitions such as
decolonization.29 At the hospital level, the likelihood of observing some of these states and
transitions is lower because of the short duration of patient stay. For example, we assumed
that the colonization lasted for the complete duration of the hospitalization because follow-
up studies have indicated that patients remained colonized 30 days after discharge.26
The increases in CDI incidence and severity and difficulties in controlling CDI have led to
the conclusion that the epidemiology of C. difficile has changed in recent years.11,30
Potential explanations include alterations in healthcare practices over the last 20 years,
increased asymptomatic carriage, increased patient susceptibility, and organism specific
factors that have increased virulence or transmission31. All these changes may have
increased transmission coefficients (e.g. the use of alcohol based hand hygiene products
over hand washing may have increased βc), increased the proportion of admitted
asymptomatic carriers (acn, acp) and diseased patients (ad) or decreased the fraction of
colonized patients capable of mounting an immune response (f), among other factors. We
evaluated the effect of modifying these epidemiological parameters in C. difficile
epidemiology. The admission of colonized patients, especially C− patients, highly influenced
C. difficile outcomes. The number of CDI cases increased as the percentage of admitted
colonized patients increased (Figure 3). In addition, the basic reproduction number ranged
from 0.55 to 1.99. These values suggest that for a wide range of parameter values,
transmission within the ward alone cannot sustain C. difficile colonization. Therefore, the
admission of colonized patients plays an important role in sustaining transmission in the
ward. An increase in the proportion of admitted patients who are already colonized may take
place as data indicate C. difficile contamination of foodstuffs is more common than
previously recognized and community-associated CDI is increasing.32,33
The number of CDI cases was also sensitive to variations in the incubation period. As the
incubation period increased, the number of cases due to transmission decreased because the
chances that an asymptomatic colonized patient leaves before becoming diseased increases.
Therefore, increased incubation periods may increase the number of patients with
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community- onset, healthcare-facility associated CDI. These patients may be readmitted
later as diseased patients. Previous research indicates patients with health-care onset CDI
were more likely to receive a fourth-generation cephalosporin or intravenous vancomycin
that were patients with community-onset healthcare facility associated CDI.34 These
antibiotics may shorten the incubation period because of their broad impact on the normal
microflora, or may be markers for sicker patients more susceptible to C. difficile.22,35 Other
influential parameters were the transmission coefficients and the fraction of patients that
mount an immune response against C. difficile. These results are supported by studies
demonstrating efforts to reduce transmission of C. difficile transmission from hands of
healthcare workers are highly effective,36 and data demonstrating the importance of the
immune response and risk of developing CDI.26
Interestingly, epidemiological parameters linked to patient susceptibility, such as
antimicrobial treatment rate, had little impact on C. difficile transmission (Figure 2). This
appears contrary to CDI prevention recommendations and data indicating antimicrobial
stewardship is effective at preventing CDI.23,37 There are several potential explanations for
this. In this study we did not differentiate between different classes of antibiotics and risk of
CDI. This may have limited our ability to detect a reduction in CDI by limiting antibiotic
exposures. A large percentage of patients were considered susceptible due to antimicrobial
treatment, therefore the rate at which the resistant patients become susceptible patients was
not a limiting factor in the C. difficile transmission. Conversely, most data to support
antimicrobial stewardship to prevent CDI occur in outbreak settings in conjunction with
other prevention efforts. It is possible antimicrobial stewardship by itself is less effective in
non-outbreak situations or in the absence of efforts to reduce C. difficile transmission.
There are some limitations to this study. Actual C. difficile colonization prevalence on
admission and at discharge from the study wards was not available. However colonization
prevalence reported in the literature was used for the parameter estimates and subsequent
assessment of colonization status conducted after the study period indicates the prevalence
of C. difficile colonization on admission and discharge at the study hospital are consistent
with the literature (5% and 15%, respectively, unpublished data). The diagnosis of CDI was
based on the result of a toxin enzyme immunoassay in patients with diarrhea. Toxin enzyme
immunoassays suffer from variable sensitivities, possibility missing true cases of CDI.37
This often results in repeat testing and subsequently increases the risk of having a false
positive result as well.38 Transmission coefficients were identified as important parameters.
Therefore, the different routes of transmission through contaminated health-care workers
and environment will need to be considered explicitly in the model to design future
interventions to prevent C. difficile transmission.
The epidemiology of C. difficile has changed dramatically in the last decade, with notable
increases in CDI incidence and severity. Current prevention recommendations appear
effective when combating CDI outbreaks, however they may be less effective at prevent
endemic CDI.39 Our study underscores the need to further evaluate the role of
asymptomatically colonized patients in C. difficile transmission and identify methods to best
prevent C. difficile transmission from these patients. The integration of C. difficile based
transmission modeling with culture-based data available post-changes in CDI epidemiology,
and the development of methods to rapidly and reliably identify asymptomatic C. difficile
carriers, are necessary to have a complete understanding on which are the most cost-
effective methods to prevent CDI, the most common healthcare-associated infection.
Lanzas et al. Page 6
Infect Control Hosp Epidemiol. Author manuscript; available in PMC 2013 May 06.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Acknowledgments
This project was supported by the Cornell University Zoonotic Research Unit of the Food and Waterborne Diseases
Integrated Research Network, funded by the National Institute of Allergy and Infectious Diseases, National
Institutes of Health, under contract number N01-AI-30054. Dr. Dubberke also received support from
1K23AI065806-01A2, 1 R21 NR011362-01,and 5 U01 CI000333-04.
APPENDIX
The deterministic differential equations for the model are as follows (parameters are defined
in Table 2):
[1]
[2]
[3]
[4]
[5]
[6]
[7]
At the free disease equilibrium, the number of susceptible (S0) can be described as a
function of antibiotic prescription (α), colonization resistance restoration (θ), discharge rates
(k, kr) and ward beds (N) as follows,
[8]
For the next generation matrix, we define the matrices F and V as
where Fi(x) is the number of new infections in the ith compartment from xj infectious
individuals and Vi(x) is the net change of individuals in the ith compartment by any other
means. The rates are evaluated at the disease free equilibrium x=x0. For the model, F and V
are given as follows:
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The next generation matrix, K, is FV−1. The entry (i,j) of K is the expected number of
secondary infections in compartment i produced by individuals initially in compartment j.
Where,
[9]
[10]
[11]
[12]
[13]
[14]
Each entry (i, j) of the K matrix represents the expected number of secondary colonizations
in compartment i produced by individuals initially in compartment j. The basic reproduction
number is the spectral radius of the matrix K,
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[15]
Stochastic model
We developed an individual-based stochastic model based on Figure 1. A combined
algorithm based on the Gillespie direct and first reaction methods was used to simulate our
individual-based stochastic model40. In our simulations, when patients were admitted to
hospital or moved to a different state, they were supposed to stay in a constant duration
(depending which state they were in) prior to discharge unless they moved to another state.
To utilize full beds in a ward, the admission was assumed to be immediate once a patient
was discharged. Our model is a modified continuous time Markov chain model, where time
is continuous, t ∈[0,∞), and the state space is discrete. The state space for the model is,
and . The probability of a transition is
We assume that Δt is sufficiently small so that the values of r, s, c−, c+, d is nonzero. There
are 11 possible changes in state where at least one of the r, s, c−, c+, d is nonzero. The
transition probabilities for the possible changes between states and five types of discharge
events are defined as follows,
Events Transition probability Changes
Restoration colonization resistance θSΔ(t) + o(Δt) r=1,s=−1
Antibiotic treatment αRΔ(t) + o(Δt) r=−1,s=1
Treatment success pεΔ(t) + o(Δt) s=1, d=−1
Colonization without immune response (1 − f)λSΔt + o(Δt) s=−1, c−=1
Colonization with immune response fλSΔt + o(Δt) s=−1, c+=1
Disease φC−Δ(t) + o(Δt) c−=−1, d=1
Duration
Discharge R 1/kr r=−1
Discharge S 1/k s=−1
Discharge C− 1/k c−=−1
Discharge C+ 1/k c+=−1
Discharge D 1/kd d=−1
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Figure 1.
Flow diagram of the epidemiological model for Clostridium difficile transmission in a
hospital ward. Five transition states are included: resistant (R), susceptible (S),
asymptomatically colonized without protection against C. difficile infection (C−),
asymptomatically colonized with protection against C. difficile infection (C+), and diseased
patients (D).
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Figure 2.
Distribution of the basic reproduction number when parameters are varied (A) and
contribution of the grouped parameters to the variation observed in the basic reproduction
number (B). We grouped the parameters within the following groups: (1) parameters that
determine patient susceptibility (as, α, θ, kr), (2) transmission (βc, βd), (3) duration of stay
of colonized individuals (k, kd), (4) treatment (ε, p), and (5) virulence (f, φ). Parameters are
defined in Table 2.
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Figure 3.
Number of new secondary cases (C− and C+) of colonization generated by each type of
admitted colonized patients (C−, C+, D).
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Figure 4.
Effect of varying the proportion of admitted colonized without immunity (acn) (A),
colonized with immunity (acp) (B), and admitted diseased (ad) (C) patients in the average
Clostridium difficile infection (CDI) cases per 1000 admissions.
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Figure 5.
Effect of varying the transmission coefficients (beta c and beta d) (A), the clinical disease
rate (phi) (B), and the fraction of colonized patients that mount immune response (C) on
Clostridium difficile infection cases per 1000 admissions. The dash line represents the
simulation with the baseline parameter values.
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Table 1
Summary of the transition states included in the epidemiological model for Clostridium difficile transmission
based on four criteria: antimicrobial treatment, presence of the toxigenic C. difficile, immune response, and
clinical symptoms.
Antimicrobial treatment Presence of toxigenic C.
difficile
Immune response
against C. difficile
C. difficile symptoms
Resistant − − − −
Susceptible + − − −
Colonized without protection + + − −
Colonized with protection + + + −
Diseased + + +/− +
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Table 2
List of parameters for the Clostridium difficile model.
Symbol Description, units Baseline value Range used in the
sensitivity analysis
Source
ar Proportion of admitted patients that are resistant, dmls1 0.75 -- Hosp. Data2
as Proportion of admitted patients that are susceptible, dmls 0.22 0.15–0.29 Estimated2
acn,acp Proportion of admitted patients that are colonized, dmls 0.01 -- Estimated
ad Proportion of admitted patients that are diseased, dmls 0.01 -- Hosp. Data
α Antibiotic prescription rate, 1/day 0.5 0.35–0.65 Hosp. Data
θ Restoration rate of colonization resistance, 1/day 0.033 0.023–0.043 22
βc,βd Transmission coefficients, 1/(ind*day) 0.007 0.004–0.01 Estimated
f Fraction of colonized patients that mount immune response, dmls 0.60 0.45–0.75 26
ε Treatment rate, 1/day 0.10 0.07–0.13 24
p Probability of successful treatment, dmls 0.80 0.56–1 24
φ Clinical disease rate, 1/day 0.2 0.14–0.26 9,25
kr Discharge rate for resistant patients, 1/day 0.33 0.23–0.43 Hosp. Data
k Discharge rate for susceptible and colonized patients, 1/day 0.15 0.105–0.195 Hosp. Data
kd Discharge rate for diseased patients, 1/day 0.068 0.048–0.088 Hosp. Data
1dmls: dimensionless,
2
Parameters obtained directly from the hospital data,
3
values set to match observed attack rate.
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